|
| Status |
Public on Dec 22, 2021 |
| Title |
ev566L_Bortezomib |
| Sample type |
RNA |
| |
|
| Source name |
snap-frozen surgical liver tissue
|
| Organism |
Homo sapiens |
| Characteristics |
tissue: liver
diagnosis: HCV-infected, F2 fibrosis
treatment group: Mono-therapy
agent: Bortezomib
|
| Treatment protocol |
Precision-cut liver slice (PCLS, 300-micron-thick) sections were generated from fresh surgical tissue, and cultured with various candidate anti-fibrotic agents desolved in DMSO for 24h at 80% O2 and 5% CO2. PCLSs were snap-frozen in RNAlater for storage until RNA isolation.
|
| Growth protocol |
na
|
| Extracted molecule |
total RNA |
| Extraction protocol |
RNA was isolated using RNeasy kit (Qiagen) according to manufacturer’s protocol.
|
| Label |
biotin
|
| Label protocol |
Refer to the NanoString nCounter Assay System Manual
|
| |
|
| Hybridization protocol |
Refer to the NanoString nCounter Assay System Manual
|
| Scan protocol |
Refer to the NanoString nCounter Assay System Manual
|
| Data processing |
Raw count data were normalized by linear normaliztion uisng R statistical language (www.r-project.org).
|
| |
|
| Submission date |
Aug 05, 2021 |
| Last update date |
Dec 22, 2021 |
| Contact name |
Yujin Hoshida |
| Organization name |
University of Texas Southwestern Medical Center
|
| Street address |
5323 Harry Hines Blvd
|
| City |
Dallas |
| State/province |
TX |
| ZIP/Postal code |
75390 |
| Country |
USA |
| |
|
| Platform ID |
GPL30481 |
| Series (2) |
| GSE85550 |
Molecular signature predictive of long-term liver fibrosis progression to inform anti-fibrotic drug development |
| GSE181538 |
Expression profiling of Prognostic Liver Signature and fibrosis-related genes in clinical fibrotic liver tissue cultured with various anti-fibrotic agents |
|
